Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
In the new COVID-19 world, it's clear how science affects our daily activities — we need research to save lives. The incredible challenges that come with a cancer diagnosis are also clear, and the new pressures and vulnerabilities brought forth by COVID-19
make navigating cancer even more difficult. The Dana-Farber and Jimmy Fund community, stronger than ever, is continuing to do everything it can to ensure that our patients and families are kept as safe as possible from transmission of the virus, and
that's why the Emergency Response Fund was created.
Our generous supporters have shown an outpouring of kindness during this time of uncertainty and are asking how to help. A donation of any size to Dana-Farber's Emergency Response Fund will support:
Supporting Dana-Farber and the Jimmy Fund through the Emergency Response Fund will allow patients to focus on their health and well-being, and ensure that Dana-Farber continues as a leader in cancer research and care. Thank you for your generosity and
partnership as we work tirelessly to keep our patients safe.
COVID-19 Novel Coronavirus – Fundraising Update
Groundbreaking research. Dedicated, compassionate care. Your support is critical to our work every day. Help us make a difference in the fight against cancer today.
Dana-Farber and the Jimmy Fund has received a 4-star rating (highest possible) from Charity Navigator, America’s largest charity evaluator, recognizing
our prudent financial management and low cost of funds raised.
Run any race, of any distance, in any city, or join an official Dana-Farber team to raise funds for Dana-Farber and the Jimmy Fund.
Walk to conquer cancer on October 3, 2021.